08 Monoclonal Antibody Facility

08 单克隆抗体设施

• 批准号: 9794663
• 负责人: Laura del Carmen Bover
• 金额: $ 19.8万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9794663
• 关键词: Affinity; Antibodies; Antibody Affinity; Antigen Targeting; Antigens; Avidity; Biotechnology; Cancer Biology; Cancer Center; Cancer Center Support Grant; Capital; Cells; Clinical; Consultations; Crystallography; Custom; Diagnosis; Equipment; Funding; Future; Generations; Goals; Grant; Hand; Human Resources; Image; Immunoglobulin Variable Region; Immunohistochemistry; Immunotherapy; In Vitro; Journals; Legal patent; Light; Mission; Monoclonal Antibodies; Names; OX40; Outcome; Pathologic; Peer Review; Peptides; Pharmacologic Substance; Phase I Clinical Trials; Price; Proteins; Publications; Research; Research Personnel; Research Support; Role; Science; Scientist; Services; System; Technology; Therapeutic Uses; Time; Training; assay development; cancer immunotherapy; clinical development; diagnostic assay; experience; hybridoma production; improved; insight; interest; member; new technology; off-patent; pre-clinical; programs; screening; tool

PROJECT SUMMARY: MONOCLONAL ANTIBODY FACILITY (MAF) The importance of immunotherapy research to advancing the field of cancer biology and improving clinical outcomes has surged in recent years, prompting Science magazine to name cancer immunotherapy its 2013 Breakthrough of the Year. Recognition of the power of immunotherapy has heightened interest in and demand for rapid, affordable monoclonal antibody (MAb) services, and improved technologies are needed to provide cutting-edge, high-quality molecules required for today's science. The Monoclonal Antibody Facility (MAF) at MD Anderson is actively participating in this endeavor. The mission of the MAF is to produce de novo MAbs against newly discovered or existing antigens, and to purify unique high-quality custom MAbs in a timely and effective manner, with the value added of scientific advice and competitive prices. Dr. Laura Bover has directed the MAF since 2007, and in 2016 hired a senior research scientist, Dr. Roberto Rangel, who is bringing additional new technologies to the core. The number of MAbs produced in grant Yr42 has tripled when compared with the average of the previous grant period (48 in Yr42 and 16 on average for the previous grant period). Four MAF- generated MAbs have been licensed to pharmaceutical companies for clinical development, and additional MAbs have been licensed to biotechnology companies for in vitro use. In addition, the MAb anti-OX40, generated in 2012, has progressed to a phase I clinical trial. In the past 6-year period, the MAF has supported the research of 72 MD Anderson center members, representing all 16 CCSG programs, in contrast to 40 investigators in the previous grant period. MD Anderson has provided an additional $717,769 in capital equipment funds. MD Anderson members with peer-reviewed funding accounted for 90% of the usage, and 35% ($128,415) support is requested from the CCSG in Yr44. MAF supported 57 publications, with 35 publications (61%) in journals with an IF of >5 and 10 publications (18%) in journals with an IF of >10. The MAF Specific Aims are: 1) To produce, in a timely, effective manner at competitive prices, unique high-affinity, high-quality custom MAbs that are suitable for diverse applications that meet the cancer center users' requirements. 2) To provide consultation and assistance, including: a) selection and generation of appropriate antigen formats (peptides, proteins, or cells expressing the target); b) troubleshooting any antigen- or screening-related issues; c) characterization of the produced antibodies (PK, affinity, avidity, and competition); d) assay development for the particular applications and users' goals, including imaging, immunohistochemistry, diagnostic assays, crystallography, and preclinical and future therapeutic use; e) advice for IND filing and patent requirements; f) training and assistance on the subsequent screening (in users' hands) of the positive candidates selected by the MAF for the particular desired application.

项目总结：单克隆抗体因子（MAF） 免疫治疗研究对推进癌症生物学领域和改善临床 近年来，癌症免疫治疗的效果激增，促使《科学》杂志将癌症免疫治疗命名为2013年 年度突破。认识到免疫疗法的力量， 快速，负担得起的单克隆抗体（MAb）服务，需要改进的技术来提供 当今科学所需的尖端高质量分子。MD的单克隆抗体设施（MAF） 安德森正在积极参与这一奋进。MAF的使命是生产针对 新发现的或现有的抗原，并及时有效地纯化独特的高质量定制单克隆抗体， 以科学的建议和有竞争力的价格增值。Laura Bover博士指导了MAF 自2007年以来，并于2016年聘请了一位高级研究科学家Roberto Rangel博士， 技术为核心。与2004年相比，2004年赠款生产的MAb数量增加了两倍。 上一个补助期的平均数（42年48人，上一个补助期平均16人）。四个MAF- 产生的单克隆抗体已被许可给制药公司用于临床开发， 已经被授权给生物技术公司用于体外使用。此外，在小鼠中产生的单克隆抗体抗OX 40， 2012年，已进展到I期临床试验。在过去的6年里，MAF一直支持这项研究 72名MD安德森中心成员，代表所有16个CCSG项目，相比之下， 上一个补助期。MD安德森提供了额外的717,769美元的资本设备资金。MD 安德森成员与同行评审的资金占90%的使用，35%（128,415美元）的支持 在第44年向CCSG提出要求。MAF支持了57篇出版物，其中35篇（61%）发表在期刊上， IF>5，10篇（18%）发表在IF>10的期刊上。MAF的具体目标是：1）生产， 及时、有效地以具有竞争力的价格，提供独特的高亲和力、高质量的定制单克隆抗体， 适用于满足癌症中心用户需求的各种应用。2)提供咨询和 辅助，包括：a）选择和产生适当的抗原形式（肽、蛋白质或细胞 表达靶标）; B）解决任何抗原或筛选相关问题; c）表征 产生的抗体（PK、亲和力、亲合力和竞争）; d）针对特定应用的测定开发 和用户的目标，包括成像，免疫组织化学，诊断分析，晶体学，和临床前 和未来的治疗用途; e）IND申请和专利要求的建议; f）关于 - 随后筛选（在用户手中）由MAF选择的用于特定期望目标的阳性候选物， 应用程序.